Browse studies
Find your next paid study
3 recruiting studies matching your filters
Phase 1
A Phase 1b/2, Safety Lead-in and Dose-Expansion, Open Label, Multicenter Trial Investigating the Safety, Tolerability, and Preliminary Activity of Ivosidenib in Combination With Durvalumab and Gemcitabine/Cisplatin as First-line Therapy in Participants With Locally Advanced, Unresectable or Metastatic Cholangiocarcinoma With an IDH1 Mutation
The objective of this study is to investigate the safety, tolerability and preliminary activity of ivosidenib in combination with durvalumab and gemcitabine/ci…
Locally Advanced, Unresectable or Metastatic Cholangiocarcinoma With an IDH1 Mutation
Estimated
~$10 – $7,500
Institut de Recherches Internationales ServierNCT06501625
Phase 1
A Phase 1/1b Trial of AB801 in Combination With Chemotherapy and PD-1/PD-L1 Blockade in Patients With Cholangiocarcinoma or Pancreatic Adenocarcinoma
This phase I trial tests the safety, side effects, best dose and effectiveness of AB801 in combination with chemotherapy and immunotherapy in treating patients…
Borderline Resectable Pancreatic Ductal AdenocarcinomaLocally Advanced CholangiocarcinomaLocally Advanced Pancreatic Adenocarcinoma+5 more
Estimated
~$10 – $6,250
Jonsson Comprehensive Cancer CenterNCT07619313
Phase 1
A Multicenter, Open-label, First-in-Human Study of TYRA-200 in Advanced Intrahepatic Cholangiocarcinoma and Other Solid Tumors With Activating FGFR2 Gene Alterations (SURF-201)
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of TYRA-200 in cancers with FGFR2 …
Locally Advanced CholangiocarcinomaIntrahepatic CholangiocarcinomaSolid Tumor+1 more
Estimated
~$10 – $8,750
Tyra Biosciences, IncNCT06160752